(6R,12aS)-6-(benzo[d][1,3]dioxol-5-yl)-2-(2-(1-benzylpiperidin-4-yl)ethyl)-2,3,12,12a-tetrahydropyrazino[1',2':1,6]pyrido[3,4-b]indole-1,4(6H,7H)-dione

ID: ALA5271210

Chembl Id: CHEMBL5271210

Max Phase: Preclinical

Molecular Formula: C35H36N4O4

Molecular Weight: 576.70

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1[C@@H]2Cc3c([nH]c4ccccc34)[C@@H](c3ccc4c(c3)OCO4)N2C(=O)CN1CCC1CCN(Cc2ccccc2)CC1

Standard InChI:  InChI=1S/C35H36N4O4/c40-32-21-38(17-14-23-12-15-37(16-13-23)20-24-6-2-1-3-7-24)35(41)29-19-27-26-8-4-5-9-28(26)36-33(27)34(39(29)32)25-10-11-30-31(18-25)43-22-42-30/h1-11,18,23,29,34,36H,12-17,19-22H2/t29-,34+/m0/s1

Standard InChI Key:  KVANOXIAOYTXBY-ZBWWXOROSA-N

Alternative Forms

  1. Parent:

    ALA5271210

    ---

Associated Targets(Human)

PDE5A Tclin Phosphodiesterase 5A (5113 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
ACHE Tclin Acetylcholinesterase (18204 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Ache Acetylcholinesterase (2577 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 576.70Molecular Weight (Monoisotopic): 576.2737AlogP: 4.88#Rotatable Bonds: 6
Polar Surface Area: 78.11Molecular Species: BASEHBA: 5HBD: 1
#RO5 Violations: 1HBA (Lipinski): 8HBD (Lipinski): 1#RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 9.28CX LogP: 4.22CX LogD: 2.34
Aromatic Rings: 4Heavy Atoms: 43QED Weighted: 0.35Np Likeness Score: -0.54

References

1. Nadur NF, de Azevedo LL, Caruso L, Graebin CS, Lacerda RB, Kümmerle AE..  (2021)  The long and winding road of designing phosphodiesterase inhibitors for the treatment of heart failure.,  212  [PMID:33412421] [10.1016/j.ejmech.2020.113123]
2. Beato A, Gori A, Boucherle B, Peuchmaur M, Haudecoeur R..  (2021)  β-Carboline as a Privileged Scaffold for Multitarget Strategies in Alzheimer's Disease Therapy.,  64  (3.0): [PMID:33528252] [10.1021/acs.jmedchem.0c01887]

Source